Haleon plc (LON:HLN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Haleon plc (LON:HLN) have received a consensus recommendation of “Hold” from the six brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is GBX 393.67.

Several analysts have recently weighed in on the stock. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a research note on Thursday, April 30th. Berenberg Bank restated a “buy” rating and set a GBX 512 target price on shares of Haleon in a report on Thursday, April 30th. Jefferies Financial Group dropped their price target on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and set a GBX 325 price objective on shares of Haleon in a research report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. dropped their target price on Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a report on Thursday, June 25th.

Haleon Stock Performance

LON HLN opened at GBX 358.50 on Thursday. The stock’s fifty day moving average is GBX 341.49 and its two-hundred day moving average is GBX 363.30. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92. The firm has a market capitalization of £31.58 billion, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. Haleon has a fifty-two week low of GBX 317.80 and a fifty-two week high of GBX 416.10.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.